Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Manuel HidalgoE K Rowinsky

Abstract

To assess the feasibility, toxicity, pharmacokinetics, and preliminary activity of BMS-184476 administered as a 1-hour intravenous (IV) infusion every 3 weeks. Patients with advanced solid malignancies were treated with escalating doses of BMS-184476 as a 1-hour IV infusion every 3 weeks without premedication to prevent hypersensitivity reactions (HSR). Plasma sampling and urine collections were performed to characterize the pharmacokinetics and pharmacodynamics of BMS-184474. Thirty-four patients were treated with 78 courses of BMS-184476 at five dose levels ranging from 20 to 80 mg/m2. Dose-limiting toxicity (DLT), consisting of severe neutropenia with fever, severe diarrhea, and/or severe mucositis, was experienced during course 1 by six of nine minimally pretreated patients treated at the 70 and 80 mg/m2 dose level. In contrast, of 15 assessable patients treated at the 60 mg/m2 dose level, which is the maximum-tolerated dose (MTD) of BMS-184476 on this administration schedule, only one heavily pretreated patient developed DLT (grade 4 neutropenia with fever and grade 3 diarrhea). One patient developed a grade 2 HSR during a second course of BMS-184476 at the 40 mg/m2 dose level. A previously untreated patient with an advanc...Continue Reading

References

Sep 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E K RowinskyS E Sartorius
Jul 11, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R B WeissB Leyland-Jones
Aug 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P J O'DwyerB Leyland-Jones
Jun 1, 1985·Drug Intelligence & Clinical Pharmacy·D L HowrieR Venkataramanan
Oct 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J E Cortes, R Pazdur
Jan 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L GianniM J Egorin
Apr 13, 1995·The New England Journal of Medicine·E K Rowinsky, R C Donehower
Mar 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D S SonnichsenM V Relling
Oct 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F A HolmesG N Hortobagyi
Apr 15, 1997·Proceedings of the National Academy of Sciences of the United States of America·A H SchinkelP Borst
Mar 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G D ZanelliM G Trovò
May 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A N GordonJ Nemunaitis
Jun 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J D HainsworthF A Greco
Jun 1, 1997·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M A BookmanR F Ozols
Jul 8, 1998·Cancer Chemotherapy and Pharmacology·H L McLeodR Bruno
Nov 27, 1998·Annals of Surgical Oncology·S S Kroll
Sep 25, 1999·British Journal of Cancer·O van TellingenJ H Beijnen

❮ Previous
Next ❯

Citations

Mar 7, 2008·Expert Opinion on Investigational Drugs·Cristiano FerliniGiovanni Scambia
Aug 20, 2002·The Cancer Journal·Jim A KriegerIan Rabinowitz
Oct 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mark HarriesPeter Harper
Nov 13, 2001·British Journal of Pharmacology·M MarkW H Reinhart
Jun 14, 2005·Cancer Investigation·Federico Pellegrini, Daniel R Budman
Jul 8, 2003·Clinical Pharmacokinetics·Albert J ten TijeAlex Sparreboom
Jun 18, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Udai BanerjiIan Judson
Oct 6, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Manuel HidalgoEric K Rowinsky
Feb 24, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sridhar ManiSusan Band Horwitz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Antoinette R TanAdrian M Senderowicz
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Alain MitaAnthony W Tolcher
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Bahram ForouzeshE K Rowinsky
© 2021 Meta ULC. All rights reserved